FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
[ad_1] Up to 78 million adults in the US are estimated to be affected by motion sickness. RealPeopleStudio via Shutterstock.com. The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting induced by motion. Nereus, taken as an oral capsule, is a new option to those who suffer…